Heritage Group

– SimBioSys announced it raised $15m in Series A funding to accelerate the development and commercialization of its TumorScope software platform.
– The company’s novel, simulation-based, precision medicine platform enables individualized treatment planning for cancer patients.
– This Series A was co-led by Genoa Ventures and Northpond Ventures, with participation from AV8 Ventures, Heritage Medical Group, and Mayo Clinic.
– Existing investors and founders also participated in this financing round, bringing the company’s total capital raised to $21m.
– In the first half of 2021, SimBioSys tripled its headcount, bringing in expert clinicians, scientists, and executives from the life sciences industry.

– Upward Health raised a significant equity financing led by Heritage Group, with participation from existing investors including Noro-Moseley Partners, the Blue Venture Fund and Windham Ventures.
– The company partners with health plans, taking on risk and guaranteeing outcomes in both cost and quality across their most complex and high-cost populations.
– The company pairs these members with care specialists who form trusted relationships and coordinate all aspects of the members’ care.
– Upward Health enables Facilitated Virtual Care™ visits with Upward Health providers and works to support and strengthen any existing member relationships with primary care physicians.